The in vivo antitumour activity of the natural photosensitizer hypericin was evaluated. C3H/DiSn mice were inoculated with fibrosarcoma G5:1:13 cells. When the tumour reached a volume of 40-80mm3 the mice were intraperitoneally injected with hypericin, either in a single dose (5mg/kg; 1 or 6h before laser irradiation) or two fractionated doses (2.5 mg/kg; 6 and 1 h before irradiation with laser light; 532 nm, 70mW/cm2, 168 J/cm2). All tumours in control groups treated with hypericin alone as well as those irradiated with laser light alone had similar growth rates and none of these tumours regressed spontaneously. Complete remission of tumour in photodynamic therapy (PDT)-treated groups was similar (14-17% single dose vs. 33% fractionated dose), but the fractionated schedule of hypericin dosing was found to be more efficient than the single dose, measured by survival assay (p < 0.05). Our experimental model showed that fractionated administration of hypericin can produce a better therapeutic response than single administration

• MeSH
• fibrosarkom farmakoterapie   MeSH
• financování vládou MeSH
• fotochemoterapie MeSH
• fotosenzibilizující látky aplikace a dávkování   farmakologie   terapeutické užití   MeSH
• fytogenní protinádorové látky aplikace a dávkování   farmakologie   terapeutické užití   MeSH
• fytoterapie MeSH
• inbrední kmeny myší MeSH
• injekce intraperitoneální MeSH
• perylen analogy a deriváty   aplikace a dávkování   farmakologie   terapeutické užití   MeSH
• rozvrh dávkování léků MeSH
• světlo MeSH
• třezalka MeSH
• zvířata MeSH
• Check Tag
• mužské pohlaví MeSH
• zvířata MeSH